Section Arrow
ENTX.NASDAQ
- Entera Bio Ltd
Quotes are at least 15-min delayed:2026/04/16 13:18 EDT
Regular Hours
Last
 1.14
-0.04 (-3.39%)
Day High 
1.22 
Prev. Close
1.18 
1-M High
1.48 
Volume 
80.53K 
Bid
1.14
Ask
1.15
Day Low
1.13 
Open
1.21 
1-M Low
0.91001 
Market Cap 
64.25M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.17 
20-SMA 1.14 
50-SMA 1.29 
52-W High 3.22 
52-W Low 0.91001 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.25/-0.68
Enterprise Value
64.51M
Balance Sheet
Book Value Per Share
0.24
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
42.00K
Operating Revenue Per Share
0.00
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
IMMPImmutep Limited0.5833+0.0393+7.22%-- 
PBMPsyence Biomedical Ltd.6.66+3.78+131.25%-- 
ALLOAllogene Therapeutics2.325+0.155+7.14%-- 
ATAIAtaiBeckley Inc4.035+0.035+0.88%-- 
ACHVAchieve Life Sciences4.7811+1.2311+34.68%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.